Tag: LLY
-
Eli Lilly (LLY) Pullback is an Opportunity
Eli Lilly (LLY) is offering opportunity on its recent pullback to $935 a share. After catching support at just under $895, it’s starting to pivot higher again. From here, we’d like to see LLY initially retest $960. Helping, sales of its diabetes and obesity medications, Mounjaro and Zepbound are still strong. Two, LLY yields 0.57%…
-
This Could be a Mega-Blockbuster for Eli Lilly
The obesity epidemic is still bursting at the seams. At the moment, 1.9 billion people are overweight, with more than 650 million considered obese. In addition, by 2022, $245 billion will be spent on products and services battling the issue. However, there may be some good news for those looking to shed extra weight. The…
-
This is Why Eli Lilly & Co. Stock Just Plunged Lower
You may want to stay clear of Eli Lilly & Co. (LLY). The stock just plummeted to $134 and could be headed to $130 near-term. All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvement. “The study of the monoclonal…
-
The Top Two Vaccine Stocks to Avoid
There’s no such thing as a perfect trial. Fortunately, there are safeguards in place to stop trials in the event of a mishap. We’ve seen two just this week, which could put a good deal of pressure on their stocks. Hopefully, the events won’t prevent these companies from moving forward for long. Shares of Eli…
-
President Trump Pushing these Two COVID-19 Stocks Higher
Days after leaving the hospital, President Trump is urging regulators to approve emergency use authorization of Regeneron’s (REGN) and Ell Lilly’s (LLY) treatments. He specifically noted that the REGN cocktail was key to his successful treatment. “We have hundreds of thousands of doses that are just about ready,” Trump said. “I have emergency use authorization all…